ALPHAMA BIOTECHNOLOGY
AlphaMa Biotechnology Co., Ltd. is a new drug R&D company driven by big data and artificial intelligence (AI). They leverage their AI technology platform and the integrated DEL-AI platform (DELAI) to develop computational models and algorithms for identifying active molecules, target verification, and hit-to-lead optimization. Their goal is to accelerate drug research and development using AI and DEL technology. They offer a range of AI-based solutions including DEL Design, DEL Construction, DEL Data Decoding, and DEL Data Analysis, as well as Multi-target Activity Profiling and ADMET Profiling. Key products include αTranslate for drug information extraction, αScaffHop for novel compound generation, αCoCrystal for co-crystal screening, αADMET for ADMET property prediction, αKinomeX for kinase inhibitor screening, and αDEL for their core DEL technology services. AlphaMa collaborates with partners to bring drugs with clinical demand to society.
ALPHAMA BIOTECHNOLOGY
AlphaMa Biotechnology Co., Ltd. is a new drug R&D company driven by big data and artificial intelligence (AI). They leverage their AI technology platform and the integrated DEL-AI platform (DELAI) to develop computational models and algorithms for identifying active molecules, target verification, and hit-to-lead optimization. Their goal is to accelerate drug research and development using AI and DEL technology. They offer a range of AI-based solutions including DEL Design, DEL Construction, DEL Data Decoding, and DEL Data Analysis, as well as Multi-target Activity Profiling and ADMET Profiling. Key products include αTranslate for drug information extraction, αScaffHop for novel compound generation, αCoCrystal for co-crystal screening, αADMET for ADMET property prediction, αKinomeX for kinase inhibitor screening, and αDEL for their core DEL technology services. AlphaMa collaborates with partners to bring drugs with clinical demand to society.